Literature DB >> 19166662

Treating hepatocellular carcinoma without liver transplantation.

Sudhanshu Gogia1, Alex S Befeler.   

Abstract

Hepatocellular carcinoma, a significant health problem throughout the world, generally occurs in the setting of cirrhosis. Choice of treatment depends on the size and location of the tumor and hepatic reserve. Liver transplantation provides the best chance for long-term survival and can be performed regardless of hepatic reserve, but it requires small tumor sizes and is available to only a few patients. All other treatments require adequate hepatic reserve. Surgical resection, percutaneous ethanol injection, and radiofrequency ablation are effective treatments for patients with good hepatic reserve and small tumors isolated to the liver. For larger and multinodular tumors, chemoembolization is the best choice. With metastasis, portal vein invasion, or large bilobar disease and intact hepatic function, modest improvements in survival have occurred with the use of sorafenib, a recently approved targeted chemotherapy agent. Patients with poor hepatic function or low performance status should receive only supportive care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19166662     DOI: 10.1007/s11894-009-0011-9

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  36 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

Authors:  H B El-Serag; A C Mason; C Key
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

4.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 5.  Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.

Authors:  Saad-M Ibrahim; Robert-J Lewandowski; Kent-T Sato; Vanessa-L Gates; Laura Kulik; Mary-F Mulcahy; Robert-K Ryu; Reed-A Omary; Riad Salem
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Regina V Tse; Maria Hawkins; Gina Lockwood; John J Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A Dawson
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

7.  Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer.

Authors:  R Yamada; K Kishi; M Sato; T Sonomura; N Nishida; K Tanaka; Y Shioyama; M Terada; M Kimura
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.

Authors:  Bao-Quan Cheng; Chong-Qi Jia; Chun-Tao Liu; Wei Fan; Qing-Liang Wang; Zong-Li Zhang; Cui-Hua Yi
Journal:  JAMA       Date:  2008-04-09       Impact factor: 56.272

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.